Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 06/11/2025 01:18 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock STAB vs. SCPS, VAXX, CALA, EVLO, CMRA, GNCAQ, GNCA, ARDS, AMPE, and CLVRShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Calithera Biosciences (CALA), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), and Clever Leaves (CLVR). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Its Competitors Scopus BioPharma Vaxxinity Calithera Biosciences Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Clever Leaves Statera Biopharma (NASDAQ:STAB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Does the MarketBeat Community prefer STAB or SCPS? Scopus BioPharma received 2 more outperform votes than Statera Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformStatera BiopharmaN/AN/AScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Does the media refer more to STAB or SCPS? In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Statera Biopharma Neutral Scopus BioPharma Neutral Is STAB or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has stronger earnings & valuation, STAB or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Which has more risk & volatility, STAB or SCPS? Statera Biopharma has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. SummaryStatera Biopharma and Scopus BioPharma tied by winning 1 of the 2 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1420.06Price / SalesN/A255.49419.32157.08Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day PerformanceN/A3.84%2.83%2.63%1 Month PerformanceN/A11.20%9.02%6.36%1 Year PerformanceN/A4.18%31.36%14.05% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-90.2%$13KN/A0.0090Gap UpCALACalithera Biosciences0.6025 of 5 stars$0.00-47.4%N/A-90.0%$10KN/A0.0060Gap DownEVLOEvelo BiosciencesN/A$0.00-75.0%N/AN/A$9KN/A0.00120Options VolumeHigh Trading VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00-66.7%N/A-99.8%$5K$3.09M0.0030Gap DownAMPEAmpio Pharmaceuticals0.2964 of 5 stars$0.00flatN/A-97.9%$3KN/A0.0020CLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560 Related Companies and Tools Related Companies Scopus BioPharma Competitors Vaxxinity Competitors Calithera Biosciences Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors Clever Leaves Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
